Rchr
J-GLOBAL ID：201901002948173652
Update date: May. 09, 2024
Takahashi Naoki
Takahashi Naoki
Research field (1)：
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (1)：
- 2017 - 2022 Detection of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer using circulating tumor DNA
Papers (59)：
-
Rin Inamoto, Naoki Takahashi, Yasuhide Yamada. Claudin18.2 in Advanced Gastric Cancer. Cancers. 2023. 15. 24
-
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, et al. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. Cancer medicine. 2023
-
Naoki Takahashi, Hiroki Hara, Kengo Nagashima, Kenro Hirata, Toshiki Masuishi, Toshihiko Matsumoto, Hisato Kawakami, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, et al. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G). BMC Cancer. 2023. 23. 1
-
Yu Aoki, Yoshiaki Nakamura, Tadamichi Denda, Takashi Ohta, Taito Esaki, Manabu Shiozawa, Kensei Yamaguchi, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, et al. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy. JCO precision oncology. 2023. 7. e2200688
-
Naoki Izawa, Toshiki Masuishi, Naoki Takahashi, Hirokazu Shoji, Yoshiyuki Yamamoto, Toshihiko Matsumoto, Keiji Sugiyama, Takeshi Kajiwara, Kentaro Kawakami, Naoki Aomatsu, et al. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial. Targeted oncology. 2023. 18. 3. 369-381
ｍore...
MISC (80)：
-
Kentaro Yamazaki, Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Yu Sunakawa, Manabu Shiozawa, Hisateru Yasui, Naoki Takahashi, Hironaga Satake, Nobuhisa Matsuhashi, et al. Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC. ANNALS OF ONCOLOGY. 2022. 33. S479-S479
-
Yoshinori Kagawa, Daisuke Kotani, Hideaki Bando, Naoki Takahashi, Tetsuya Hamaguchi, Akiyoshi Kanazawa, Takeshi Kato, Koji Ando, Hironaga Satake, Eiji Shinozaki, et al. Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials. JOURNAL OF CLINICAL ONCOLOGY. 2022. 40. 16
-
Satoshi Yuki, Yu Sunakawa, Kentaro Yamazaki, Hiromichi Shirasu, Hiroya Taniguchi, Toshiki Masuishi, Manabu Shiozawa, Hideaki Bando, Tomohiro Nishina, Hisateru Yasui, et al. Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study. JOURNAL OF CLINICAL ONCOLOGY. 2022. 40. 16
-
澤田 武, 久保田 英嗣, 中村 慶史, 高橋 直樹, 太田 亮介, 井戸川 雅史, 佐々木 泰史, 時野 隆至, 源 利成, 片岡 洋望. RAS野生型転移性大腸癌患者における循環腫瘍DNA中のRAS、BRAF、PIK3CA変異の同定と腫瘍組織の変異との比較. 日本癌学会総会記事. 2021. 80回. [P15-6]
-
Yu Sunakawa, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Hironaga Satake, Akiyoshi Kanazawa, et al. Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study. JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 15
ｍore...
Work history (1)：
- 2017/04 - 現在 Saitama Cancer Center
Return to Previous Page
